NEW YORK--(BUSINESS WIRE)--Pathway to Cures (P2C) announced today its inaugural investment of $250,000 in Anvesana to develop therapies for treating inheritable blood and bleeding disorders. Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community..

纽约-（商业线）-治愈途径（P2C）今天宣布在Anvesana就职投资25万美元，开发治疗遗传性血液和出血性疾病的疗法。国家出血性疾病基金会的附属机构“治愈途径”是一家风险慈善基金，专注于开发治疗，治疗或支持可遗传性血液和出血性疾病社区的技术的早期公司。。

Anvesana is developing therapeutics that modulate mRNA biology to treat inheritable bleeding disorders such as hemophilia, as well as neurodegeneration and metabolic syndrome caused by insufficient protein production. The company’s RNA-sequence analysis platform provides insights into the underlying biology, rapidly prioritizing the right RNA species to target for a given disease.

Anvesana正在开发调节mRNA生物学的治疗剂，以治疗遗传性出血性疾病，如血友病，以及由蛋白质生产不足引起的神经变性和代谢综合征。该公司的RNA序列分析平台提供了对潜在生物学的深入了解，可以快速确定针对特定疾病的正确RNA种类。

Anvesana’s platform consists of a distributed database that stores and searches thousands of RNA sequence datasets and a proprietary reference transcriptome containing over 250,000 annotations curated by a team of over 40 scientists. By leveraging the database and the reference transcriptome, Anvesana’s algorithms filter out many of the biological artifacts that doom otherwise promising RNA therapeutic programs..

Anvesana的平台由一个分布式数据库组成，该数据库存储和搜索数千个RNA序列数据集和一个专有的参考转录组，其中包含由40多名科学家组成的超过250000个注释。通过利用数据库和参考转录组，Anvesana的算法过滤掉了许多其他有希望的RNA治疗程序的生物制品。。

“Anvesana is delighted to be working with Pathway to Cures to develop therapeutics that will bring life altering cures to individuals suffering from the devastating effects of inheritable blood and bleeding disorders,” said Eric Ekland, PhD., CEO of Anvesana.

埃里克·埃克兰（Eric Ekland）博士说：“Anvesana很高兴能够与治疗途径合作开发治疗方法，为遭受可遗传血液和出血性疾病破坏性影响的个人带来改变生命的治疗方法。”。，Anvesana首席执行官。

“Being able to support Anvesana in its early-stage research is an incredible step in launching our investment strategy to attract the best science and technology to the inheritable blood and bleeding disorder space,” said Teri Willey, Managing Director for Pathway to Cures. “Their unique scientific approach combined with our ability to help support their understanding of the challenges specific to the community of patients living with inheritable blood and bleeding disorders is a critical step toward addressing the unmet needs through innovative treatments.

“能够在早期研究中支持Anvesana是启动我们的投资战略，将最佳科学技术吸引到可遗传的血液和出血障碍空间的一个令人难以置信的步骤，”治愈途径总经理Teri Willey说。“他们独特的科学方法与我们帮助他们理解遗传性血液和出血性疾病患者群体特有挑战的能力相结合，是通过创新治疗解决未满足需求的关键一步。

It is our hope this will be the first of many companies we can support in their journey to bring cures to patients.”.

我们希望这将成为我们在旅程中能够支持的第一家为患者带来治疗的公司。”。

P2C brings investment dollars, knowledge, scientific, and community relationships together to facilitate development of new products to address the unmet needs of the blood and bleeding disorders community. P2C’s Scientific Advisory Group makes recommendations to the P2C Investment Committee regarding promising opportunities.

P2C将投资美元，知识，科学和社区关系结合在一起，以促进新产品的开发，以满足血液和出血性疾病社区未满足的需求。P2C的科学咨询小组就有希望的机会向P2C投资委员会提出建议。

Inheritable blood and bleeding disorders include rare and ultra-rare blood disorders, hemophilia A and B, von Willebrand disease, sickle cell disease, anemia, clotting disorders, and other hematological disorders, affecting more than 20 million people worldwide..

遗传性血液和出血性疾病包括罕见和超罕见血液疾病，血友病A和B，血管性血友病，镰状细胞病，贫血，凝血障碍和其他血液疾病，影响全球2000多万人。。

For more information, visit www.pathwaytocures.org or contact Renee Peck at rpeck@pathwaytocures.org.

欲了解更多信息，请访问www.pathwaytocures.org或联系Renee Peckrpeck@pathwaytocures.org.

About Pathway to Cures

关于治愈的途径

Pathway to Cures (P2C) is a venture philanthropy fund created to accelerate development of cures across all inheritable blood and bleeding disorders. In collaboration with other organizations, P2C invests in innovative therapies and technologies, leveraging the deep resources and scientific community relationships of its parent organization, the National Bleeding Disorders Foundation.

治愈途径（P2C）是一家创业慈善基金，旨在加速所有可遗传性血液和出血性疾病的治愈。P2C与其他组织合作，利用其母组织国家出血性疾病基金会的深层资源和科学界关系，投资于创新疗法和技术。

By reinvesting proceeds from investments back into the Fund, P2C will amplify investment impact, support promising companies, and build a portfolio of investments that further the mission of the National Bleeding Disorders Foundation..

通过重新投资回基金的收益，P2C将扩大投资影响，支持有前途的公司，并建立一套投资组合，进一步推动国家出血性疾病基金会的使命。。

About National Bleeding Disorders Foundation

关于国家出血性疾病基金会

The National Bleeding Disorders Foundation is dedicated to finding cures for inheritable blood and bleeding disorders and to addressing and preventing the complications of these disorders through research, education, and advocacy, enabling people and families to thrive. For more information, visit hemophilia.org..

国家出血性疾病基金会致力于寻找可遗传的血液和出血性疾病的治疗方法，并通过研究，教育和倡导来解决和预防这些疾病的并发症，使人们和家庭能够壮成长。欲了解更多信息，请访问hemophilia.org。。